Boman K, Larsson AH, Segersten U et al (2013) Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer 108:2321–2328. https://doi.org/10.1038/bjc.2013.215

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao W, Chen HD, Yu YW et al (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134:783–791. https://doi.org/10.1097/cm9.0000000000001474

Article  PubMed  Google Scholar 

Chen Z, Lu X, Xuan Y et al (2019) Transcriptome analysis based on a combination of sequencing platforms provides insights into leaf pigmentation in Acer rubrum. BMC Plant Biol 19:240. https://doi.org/10.1186/s12870-019-1850-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding Y, Wang X, Lu S et al (2023) BCAT1, as a prognostic factor for HCC, can promote the development of liver cancer through activation of the AKT signaling pathway and EMT. J Mol Histol 54:25–39. https://doi.org/10.1007/s10735-022-10108-3

Article  CAS  PubMed  Google Scholar 

Flores-Tellez TN, Lopez TV, Vasquez Garzon VR et al (2015) Co-expression of Ezrin-CLIC5-Podocalyxin is Associated with Migration and Invasiveness in Hepatocellular Carcinoma. PLoS ONE 10:e0131605. https://doi.org/10.1371/journal.pone.0131605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma, Lancet. 391:1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2

Han X, Yabroff KR, Ward E et al (2018) Comparison of insurance status and diagnosis stage among patients with newly diagnosed Cancer before vs after implementation of the Patient Protection and Affordable Care Act. JAMA Oncol 4:1713–1720. https://doi.org/10.1001/jamaoncol.2018.3467

Article  PubMed  PubMed Central  Google Scholar 

Huang T, Jin X, He L et al (2013) Role of podocalyxin in astrocytoma: clinicopathological and in vitro evidence. Oncol Lett 6:1390–1396. https://doi.org/10.3892/ol.2013.1556

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang R, Wu J, Zheng Z et al (2019) The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Mesothelioma with Bone Metastasis. Front Bioeng Biotechnol 7:257. https://doi.org/10.3389/fbioe.2019.00257

Article  PubMed  PubMed Central  Google Scholar 

Ito T, Nguyen MH (2023) Perspectives on the underlying etiology of HCC and its effects on Treatment outcomes. J Hepatocell Carcinoma 10:413–428. https://doi.org/10.2147/jhc.S347959

Article  PubMed  PubMed Central  Google Scholar 

Kaprio T, Fermer C, Hagstrom J et al (2014) Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer 14:493. https://doi.org/10.1186/1471-2407-14-493

Article  PubMed  PubMed Central  Google Scholar 

Kelley TW, Huntsman D, McNagny KM et al (2005) Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 124:134–142. https://doi.org/10.1309/7bhlahhu0n4mht7q

Article  PubMed  Google Scholar 

Koch LK, Zhou H, Ellinger J et al (2008) Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Hum Pathol 39:1597–1605. https://doi.org/10.1016/j.humpath.2008.03.008

Article  CAS  PubMed  Google Scholar 

Kusumoto H, Shintani Y, Kanzaki R et al (2017) Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma. Cancer Sci 108:528–535. https://doi.org/10.1111/cas.13142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laitinen A, Bockelman C, Hagstrom J et al (2015) Podocalyxin as a prognostic marker in gastric Cancer. PLoS ONE 10:e0145079. https://doi.org/10.1371/journal.pone.0145079

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larsson A, Johansson ME, Wangefjord S et al (2011) Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 105:666–672. https://doi.org/10.1038/bjc.2011.295

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei T, Zhu X, Zhu K et al (2019) EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Cancer Biol Ther 20:1007–1016. https://doi.org/10.1080/15384047.2019.1595276

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv QL, Wang LC, Li DC et al (2020) Knockdown lncRNA DLEU1 inhibits gliomas progression and promotes Temozolomide Chemosensitivity by regulating Autophagy. Front Pharmacol 11:560543. https://doi.org/10.3389/fphar.2020.560543

Article  CAS  PubMed  PubMed Central  Google Scholar 

Napoli M, Li X, Ackerman HD et al (2020) Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun 11:5156. https://doi.org/10.1038/s41467-020-18973-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker BJ, Wearsch PA, Veloo ACM et al (2020) The Genus Alistipes: gut Bacteria with emerging implications to inflammation, Cancer, and Mental Health. Front Immunol 11:906. https://doi.org/10.3389/fimmu.2020.00906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rong Z, Luo Z, Zhang J et al (2020) GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4, promotes the growth of colorectal cancer. Cancer Sci 111:1203–1217. https://doi.org/10.1111/cas.14341

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schopperle WM, Kershaw DB, DeWolf WC (2003) Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 300:285–290. https://doi.org/10.1016/s0006-291x(02)02844-9

Article  PubMed  Google Scholar 

Somasiri A, Nielsen JS, Makretsov N et al (2004) Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64:5068–5073. https://doi.org/10.1158/0008-5472.Can-04-0240

Article  CAS  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Tamayo-Orbegozo E, Amo L, Riñón M et al (2017) Podocalyxin promotes proliferation and survival in mature B-cell non-hodgkin lymphoma cells. Oncotarget 8:99722–99739. https://doi.org/10.18632/oncotarget.21283

Article  PubMed  PubMed Central  Google Scholar 

Tang F, Gao R, Jeevan-Raj B et al (2019) LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. Nat Commun 10:5755. https://doi.org/10.1038/s41467-019-13591-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taniuchi K, Furihata M, Naganuma S et al (2016) Podocalyxin-like protein, linked to poor prognosis of pancreatic cancers, promotes cell invasion by binding to gelsolin. Cancer Sci 107:1430–1442. https://doi.org/10.1111/cas.13018

Article  CAS  PubMed  PubMed Central